{"id":"interferon","rwe":[{"pmid":"41912985","year":"2026","title":"Associations between sleep disturbance and cerebrospinal fluid Aβ, and shared proteomic signatures in Alzheimer's disease.","finding":"","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","studyType":"Clinical Study"},{"pmid":"41912776","year":"2026","title":"Dual function of DOT1L suppresses tumor cell-intrinsic immunogenicity in hepatocellular carcinoma.","finding":"","journal":"Oncogene","studyType":"Clinical Study"},{"pmid":"41912663","year":"2026","title":"Neuroimmune interferon signals sustain arthritis pain.","finding":"","journal":"Nature neuroscience","studyType":"Clinical Study"},{"pmid":"41912489","year":"2026","title":"The RASSF1C-HIF-1α axis drives macrophage lipid metabolism to promote pancreatic cancer.","finding":"","journal":"Cell death & disease","studyType":"Clinical Study"},{"pmid":"41912268","year":"2026","title":"Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.","finding":"","journal":"Journal for immunotherapy of cancer","studyType":"Clinical Study"}],"_fda":{"id":"2b563c1a-771f-eb3f-e063-6394a90a618f","set_id":"23886c49-5992-4a59-af52-e24eb3c9fbc5","openfda":{"nui":["N0000178328","N0000009391","M0011506","N0000175667","N0000185371","N0000185375","N0000175629","N0000184306","M0000728","M0006342","M0016962","N0000185015","N0000175541","M0011490"],"unii":["M89N0Q7EQR","751635Z921","37CQ2C7X93","7M867G6T1U","0MVO31Q3QS","92QVL9080Y","21K6M2I7AG","6WS4C399GB","2A88ZO081O","VP2CN2G7Y8","308LM01C72","7B69B0BD62"],"route":["ORAL"],"spl_id":["2b563c1a-771f-eb3f-e063-6394a90a618f"],"brand_name":["CITOMIX"],"spl_set_id":["23886c49-5992-4a59-af52-e24eb3c9fbc5"],"package_ndc":["17089-076-20"],"product_ndc":["17089-076"],"generic_name":["ALDESLEUKIN - BINETRAKIN - CANAKINUMAB - CENTELLA ASIATICA - CRANBERRY - HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) - INTERFERON GAMMA-1B - LENOGRASTIM - PINEAPPLE - SUS SCROFA BONE MARROW - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA THYMUS -"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Interleukin-2 [CS]","Allergens [CS]","Dietary Proteins [CS]","Plant Proteins [CS]","Interferon-gamma [CS]"],"pharm_class_pe":["Increased Lymphocyte Activation [PE]","Increased Lymphocyte Cell Production [PE]","Increased Histamine Release [PE]","Cell-mediated Immunity [PE]"],"substance_name":["ALDESLEUKIN","BINETRAKIN","CANAKINUMAB","CENTELLA ASIATICA","CRANBERRY","HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED)","INTERFERON GAMMA-1B","LENOGRASTIM","PINEAPPLE","SUS SCROFA BONE MARROW","SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE","SUS SCROFA THYMUS"],"pharm_class_epc":["Lymphocyte Growth Factor [EPC]","Non-Standardized Food Allergenic Extract [EPC]","Non-Standardized Plant Allergenic Extract [EPC]","Interferon gamma [EPC]"],"manufacturer_name":["Guna spa"],"is_original_packager":[true]},"purpose":["USES Immune Support during times of: seasonal colds and flu"],"version":"8","stop_use":["WARNINGS Stop use and ask doctor if symptoms persist more than 5 days or worsen."],"warnings":["Stop use and ask doctor if symptoms persist more than 5 days or worsen. If pregnant or breast-feeding ask a health professional before use. Keep out of reach of children."],"questions":["QUESTIONS Questions?: info@gunainc.com tel. (484) 223-3500"],"when_using":["DIRECTIONS Turn tube upside down and rotate cap to release pellets into cap. Unscrew cap and without touching pellets tip them into the mouth under the tongue. Allow to dissolve Take 15 minutes before meals."],"effective_time":"20250110","active_ingredient":["ACTIVE INGREDIENTS/PURPOSE ANANASSA SATIVA 3X RELIEVES INFLAMMATION GCSF 4C, 9C, 15C, 30C, INTERFERON GAMMA 4C IMMUNE SUPPORT INTERLEUKIN 1 BETA 5C, INTERLEUKIN 2 5C, 7C, INTERLEUKIN 4 4C IMMUNE SUPPORT INTERLEUKIN 6 7C, 9C, 15C, THYMUS GLAND 4C IMMUNE SUPPORT HYDROCOTYLE ASIATICA 3X RELIEVES COLD SYMPTOMS LYMPHATIC VESSEL 4C, MOUNTAIN CRANBERRY 3X RELIEVES INFLAMMATION, SWELLING, RESPIRATORY CONGESTION MEDULLA OSSIS 4C RELIEVES NASAL CONGESTION"],"inactive_ingredient":["Inactive ingredient : Sucrose."],"indications_and_usage":["Immune support suring times of: Seasonal colds and flu"],"dosage_and_administration":["Take 15 minutes before meals Adults and children 12 years and older 5 pellets 3 times per day Children between 12 years and 6 years of age 3 pellets 3 times per day Children under 6 years 1 pellet 3 times per day to be disoolved into a little water"],"spl_product_data_elements":["CITOMIX ALDESLEUKIN - BINETRAKIN - CANAKINUMAB - CENTELLA ASIATICA - CRANBERRY - HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) - INTERFERON GAMMA-1B - LENOGRASTIM - PINEAPPLE - SUS SCROFA BONE MARROW - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA THYMUS - SUCROSE PINEAPPLE PINEAPPLE LENOGRASTIM LENOGRASTIM CENTELLA ASIATICA CENTELLA ASIATICA INTERFERON GAMMA-1B INTERFERON GAMMA-1B CANAKINUMAB CANAKINUMAB ALDESLEUKIN ALDESLEUKIN BINETRAKIN BINETRAKIN HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE SUS SCROFA BONE MARROW SUS SCROFA BONE MARROW CRANBERRY CRANBERRY SUS SCROFA THYMUS SUS SCROFA THYMUS white"],"pregnancy_or_breast_feeding":["PREGNANCY If pregnant or breast-feeding ask a health care professional before use."],"keep_out_of_reach_of_children":["WARNINGS Keep this and all medicines out of reach of children","Keep out of reach of children"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL 5USCIT-E"]},"tags":[{"label":"Lymphocyte Growth Factor [EPC]","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"Vial","category":"form"},{"label":"Active","category":"status"},{"label":"Seasonal colds","category":"indication"},{"label":"Bayer Healthcare Pharms","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"MULTIPLE SCLEROSIS RELAPSE","source":"FDA FAERS","actionTaken":"16997 reports"},{"date":"","signal":"INFLUENZA LIKE ILLNESS","source":"FDA FAERS","actionTaken":"14667 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"12714 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"11331 reports"},{"date":"","signal":"MULTIPLE SCLEROSIS","source":"FDA FAERS","actionTaken":"10389 reports"},{"date":"","signal":"GAIT DISTURBANCE","source":"FDA FAERS","actionTaken":"9615 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"9251 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"8589 reports"},{"date":"","signal":"MEMORY IMPAIRMENT","source":"FDA FAERS","actionTaken":"8287 reports"},{"date":"","signal":"INJECTION SITE PAIN","source":"FDA FAERS","actionTaken":"7517 reports"}],"commonSideEffects":[{"effect":"Fever","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Chills","drugRate":"","severity":"common","organSystem":""},{"effect":"Injection site erythema","drugRate":"","severity":"common","organSystem":""},{"effect":"Injection site tenderness","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Pancreatitis with fatal outcome","drugRate":"","severity":"serious"},{"effect":"Acute myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Cardiac failure","drugRate":"","severity":"serious"},{"effect":"Acute renal failure","drugRate":"","severity":"serious"},{"effect":"Pulmonary embolism","drugRate":"","severity":"serious"},{"effect":"Stevens-Johnson syndrome","drugRate":"","severity":"serious"},{"effect":"Convulsion/seizure","drugRate":"","severity":"serious"},{"effect":"Interstitial pneumonitis","drugRate":"","severity":"serious"},{"effect":"Granulomatous colitis","drugRate":"","severity":"serious"},{"effect":"Gastrointestinal bleeding","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Bayer Healthcare Pharms","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=INTERFERON","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:40:02.149915+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:40:07.692724+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:40:01.269734+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=INTERFERON","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:40:08.078347+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:54.516509+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:54.516533+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:54.516538+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:40:09.730024+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108506/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:40:08.875103+00:00"}},"allNames":"citomix","offLabel":[],"synonyms":["Citomix","ALDESLEUKIN"],"timeline":[{"date":"20151222","type":"positive","source":"OpenFDA","milestone":"FDA approval (Bayer Healthcare Pharms)"}],"aiSummary":"Citomix (interferon) is a lymphocyte growth factor developed by Bayer Healthcare Pharmaceuticals. It is a small molecule drug that was approved by the FDA in 2015 for the treatment of seasonal colds. As a lymphocyte growth factor, Citomix works by stimulating the growth and activity of immune cells, helping to fight off infections. The commercial status of Citomix is patented, and it is currently owned by Bayer Healthcare Pharmaceuticals. Key safety considerations include potential side effects such as flu-like symptoms and injection site reactions.","approvals":[{"date":"20151222","orphan":false,"company":"BAYER HEALTHCARE PHARMS","regulator":"FDA"}],"brandName":"Citomix","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Lymphocyte Growth Factor [EPC]","explanation":"","oneSentence":"","technicalDetail":"Citomix is a recombinant interferon that acts as a cytokine, binding to specific receptors on the surface of immune cells to activate signaling pathways that promote cell growth and differentiation."},"commercial":{"launchDate":"2015","_launchSource":"OpenFDA (20151222, BAYER HEALTHCARE PHARMS)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"INTERFERON\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"INTERFERON\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=interferon","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=interferon","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:35:20.642903","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:40:11.007319+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"interferon","indications":{"approved":[{"name":"Seasonal colds","source":"OpenFDA Label","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05895786","phase":"PHASE3","title":"A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-20","conditions":["Myositis"],"enrollment":318,"completionDate":"2027-07-28"},{"nctId":"NCT06510374","phase":"PHASE3","title":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":["Intermediate Risk Non-Muscle Invasive Bladder Cancer"],"enrollment":454,"completionDate":"2031-06-30"},{"nctId":"NCT02506153","phase":"PHASE3","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-10","conditions":["Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Cutaneous Melanoma","Metastatic Mucosal Melanoma","Metastatic Non-Cutaneous Melanoma","Non-Cutaneous Melanoma","Recurrent Cutaneous Melanoma","Recurrent Mucosal Melanoma","Recurrent Non-Cutaneous Melanoma"],"enrollment":1301,"completionDate":"2027-01-23"},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":["Colorectal Neuroendocrine Tumor G1","Gastric Neuroendocrine Tumor G1","Neuroendocrine Neoplasm","Neuroendocrine Tumor","Neuroendocrine Tumor G2"],"enrollment":427,"completionDate":"2027-01-31"},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":["Lymphoproliferative Disorder","HHV-8","Malignancy","HIV"],"enrollment":75,"completionDate":"2026-10-01"},{"nctId":"NCT05463133","phase":"PHASE1,PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":["Chronic Granulomatous Disease"],"enrollment":50,"completionDate":"2032-12-31"},{"nctId":"NCT06698796","phase":"PHASE3","title":"A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-22","conditions":["Dermatomyositis","Polymyositis"],"enrollment":211,"completionDate":"2027-11-25"},{"nctId":"NCT06568484","phase":"PHASE2,PHASE3","title":"Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-07","conditions":["Tuberculosis, Latent"],"enrollment":2530,"completionDate":"2027-09"},{"nctId":"NCT01212003","phase":"","title":"Training Protocol on the Natural History of Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-06-30","conditions":["Mycobacterium Infections","Tuberculosis, Multidrug-Resistant","Latent Tuberculosis","Tuberculosis","Extensively Drug-Resistant Tuberculosis"],"enrollment":150,"completionDate":""},{"nctId":"NCT03328026","phase":"PHASE1,PHASE2","title":"Combination Study of SV-BR-1-GM With Retifanlimab","status":"COMPLETED","sponsor":"BriaCell Therapeutics Corporation","startDate":"2018-03-16","conditions":["Breast Cancer","Breast Neoplasm","Metastatic Breast Cancer","Breast Cancer Metastatic"],"enrollment":36,"completionDate":"2026-03-24"},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":["B-Cell Non-Hodgkin Lymphoma","Histiocytic and Dendritic Cell Neoplasm","Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome","Recurrent Adult Acute Myeloid Leukemia","Recurrent Anaplastic Large Cell Lymphoma","Recurrent Angioimmunoblastic T-Cell Lymphoma","Recurrent Mycosis Fungoides","Recurrent Plasma Cell Myeloma","Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Acute Myeloid Leukemia","Refractory Anaplastic Large Cell Lymphoma","Refractory Angioimmunoblastic T-Cell Lymphoma","Refractory Mycosis Fungoides","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Refractory Plasma Cell Myeloma","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma"],"enrollment":127,"completionDate":"2032-04-01"},{"nctId":"NCT05104723","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-12","conditions":["Chronic Granulomatous Disease","Inflammatory Gastrointestinal Disease","Inflammatory Skin Disease","Inflammatory Lung Disease"],"enrollment":20,"completionDate":"2027-01-01"},{"nctId":"NCT04926922","phase":"","title":"PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-27","conditions":["Tuberculosis","HIV"],"enrollment":200,"completionDate":"2026-06-07"},{"nctId":"NCT07355218","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":["Systematic Lupus Erythematosus","Cutaneous Lupus Erythematosus"],"enrollment":202,"completionDate":"2029-05-25"},{"nctId":"NCT00814827","phase":"","title":"Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01-07","conditions":["Nontuberculous Mycobacteria","Mycobacterium Tuberculosis","Opportunistic Infections"],"enrollment":224,"completionDate":""},{"nctId":"NCT07332481","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":["Systemic Lupus Erythematosus (SLE)","Cutaneous Lupus Erythematosus (CLE)"],"enrollment":202,"completionDate":"2029-05-24"},{"nctId":"NCT06053749","phase":"","title":"An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-03-20","conditions":["Multiple Sclerosis (MS)"],"enrollment":4,"completionDate":"2026-03-31"},{"nctId":"NCT06795893","phase":"","title":"The Anifrolumab PRIM Program","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-07","conditions":["Systemic Lupus Erythematosus"],"enrollment":240,"completionDate":"2031-04-15"},{"nctId":"NCT06357806","phase":"NA","title":"The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-05-17","conditions":["Chronic Hepatitis B"],"enrollment":45,"completionDate":"2026-10-08"},{"nctId":"NCT06508463","phase":"PHASE1","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":["Peripheral T Cell Lymphoma","Relapsed Peripheral T-Cell Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Anaplastic Large Cell Lymphoma","Mycosis Fungoides","Relapsed Anaplastic Large Cell Lymphoma","Relapsed Mycosis Fungoides"],"enrollment":21,"completionDate":"2032-04-01"},{"nctId":"NCT06659029","phase":"","title":"Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-01","conditions":["Systemic Lupus Erythematosus"],"enrollment":442,"completionDate":"2031-04-15"},{"nctId":"NCT07332351","phase":"PHASE2","title":"Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-06-01","conditions":["Muscle Invasive Bladder Urothelial Carcinoma","Stage II Bladder Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8"],"enrollment":33,"completionDate":"2027-02-01"},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":["Essential Thrombocythemia"],"enrollment":340,"completionDate":"2028-08-18"},{"nctId":"NCT07468916","phase":"PHASE2","title":"Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-03-29","conditions":["Atypical Chronic Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic/Myeloproliferative Neoplasm","Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified"],"enrollment":35,"completionDate":"2032-03-30"},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":["HIV I Infection","Tuberculosis"],"enrollment":276,"completionDate":"2027-04-05"},{"nctId":"NCT06439914","phase":"PHASE1","title":"First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy","status":"RECRUITING","sponsor":"Nerissa T. Viola","startDate":"2026-03-09","conditions":["Non Small Cell Lung Cancer"],"enrollment":6,"completionDate":"2029-06"},{"nctId":"NCT02737046","phase":"PHASE2","title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-12-12","conditions":["Adult T-cell Leukemia-Lymphoma","ATLL"],"enrollment":15,"completionDate":"2025-12-31"},{"nctId":"NCT06551519","phase":"","title":"A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-28","conditions":["Multiple Sclerosis"],"enrollment":700,"completionDate":"2028-11-29"},{"nctId":"NCT05344469","phase":"","title":"A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":["Relapsing Multiple Sclerosis"],"enrollment":800,"completionDate":"2029-05-30"},{"nctId":"NCT04380545","phase":"PHASE1,PHASE2","title":"Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-13","conditions":["Stage III Hepatocellular Carcinoma AJCC v8","Stage IIIA Hepatocellular Carcinoma AJCC v8","Stage IIIB Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IVA Hepatocellular Carcinoma AJCC v8","Stage IVB Hepatocellular Carcinoma AJCC v8","Unresectable Fibrolamellar Carcinoma"],"enrollment":15,"completionDate":"2028-02-28"},{"nctId":"NCT04705818","phase":"PHASE2","title":"Combining Epigenetic And Immune Therapy to Beat Cancer.","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2021-07-23","conditions":["Advanced Solid Tumor","Advanced Colorectal Carcinoma","Advanced Soft-tissue Sarcoma","Advanced Pancreatic Adenocarcinoma","Adult Solid Tumor"],"enrollment":164,"completionDate":"2025-07-17"},{"nctId":"NCT01125228","phase":"","title":"Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1988-10-19","conditions":["HIV"],"enrollment":180,"completionDate":""},{"nctId":"NCT06594068","phase":"PHASE4","title":"Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-16","conditions":["Systemic Lupus Erythematosus"],"enrollment":16,"completionDate":"2027-08-31"},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":["Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"],"enrollment":250,"completionDate":"2030-12-31"},{"nctId":"NCT07232290","phase":"PHASE2","title":"Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2025-09-23","conditions":["Polycythemia Vera (PV)"],"enrollment":60,"completionDate":"2028-02-28"},{"nctId":"NCT07449286","phase":"PHASE2","title":"IFN-α in Relapse Prevention.","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-01","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":100,"completionDate":"2027-06-30"},{"nctId":"NCT04788615","phase":"PHASE3","title":"Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-23","conditions":["Multiple Sclerosis"],"enrollment":185,"completionDate":"2025-11-04"},{"nctId":"NCT07445893","phase":"NA","title":"A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV","status":"NOT_YET_RECRUITING","sponsor":"Duan Minghui","startDate":"2026-02-24","conditions":["Polycythemia Vera (PV)"],"enrollment":30,"completionDate":"2028-12-30"},{"nctId":"NCT00003641","phase":"PHASE3","title":"High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1999-03-25","conditions":["Melanoma (Skin)"],"enrollment":1150,"completionDate":"2026-12"},{"nctId":"NCT04093323","phase":"PHASE2","title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-13","conditions":["HLA-A2 Positive Cells Present","Refractory Melanoma"],"enrollment":1,"completionDate":"2025-06-19"},{"nctId":"NCT07431775","phase":"","title":"Saphnelo Use in Females of Child-bearing Potential","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-10-01","conditions":["Systemic Lupus Erythematosus"],"enrollment":26000000,"completionDate":"2032-03-31"},{"nctId":"NCT01274338","phase":"PHASE3","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-25","conditions":["Melanoma of Unknown Primary","Recurrent Melanoma","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7"],"enrollment":1673,"completionDate":"2026-03-19"},{"nctId":"NCT05440422","phase":"PHASE2","title":"The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2023-12-07","conditions":["Systemic Lupus Erythematosus","Cardiovascular Disease","Premature Atherosclerosis"],"enrollment":45,"completionDate":"2027-08-02"},{"nctId":"NCT07040774","phase":"","title":"Natural History of Type 1 Interferonopathies: Insights From a European Cohort","status":"RECRUITING","sponsor":"Imagine Institute","startDate":"2025-10-01","conditions":["Genetic Disease","Immune Dysfunction","Neurological Diseases or Conditions","Autoimmune Diseases"],"enrollment":500,"completionDate":"2045-10"},{"nctId":"NCT05799612","phase":"PHASE1","title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-22","conditions":["Angiosarcoma"],"enrollment":0,"completionDate":"2024-11-05"},{"nctId":"NCT04328714","phase":"PHASE1","title":"Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease","status":"TERMINATED","sponsor":"Edwin Horwitz","startDate":"2021-12-02","conditions":["Acute Leukemia","Myelodysplastic Syndromes"],"enrollment":4,"completionDate":"2022-07-20"},{"nctId":"NCT03866109","phase":"PHASE1,PHASE2","title":"A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genenta Science","startDate":"2019-03-05","conditions":["Glioblastoma Multiforme"],"enrollment":27,"completionDate":"2026-06-30"},{"nctId":"NCT06052839","phase":"PHASE2","title":"Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2023-10-03","conditions":["Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)"],"enrollment":15,"completionDate":"2027-12-31"},{"nctId":"NCT06716853","phase":"PHASE1,PHASE2","title":"A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Genenta Science","startDate":"2024-10-22","conditions":["Clear Cell RCC"],"enrollment":10,"completionDate":"2026-01-23"},{"nctId":"NCT03120624","phase":"PHASE1","title":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-09-15","conditions":["Metastatic Endometrial Carcinoma","Recurrent Endometrial Adenocarcinoma","Recurrent Endometrial Carcinoma","Recurrent Endometrial Clear Cell Adenocarcinoma","Recurrent Endometrial Endometrioid Adenocarcinoma","Recurrent Endometrial Mixed Cell Adenocarcinoma","Recurrent Endometrial Serous Adenocarcinoma","Recurrent Endometrial Undifferentiated Carcinoma","Recurrent Uterine Corpus Carcinosarcoma","Stage IV Uterine Corpus Cancer AJCC v7"],"enrollment":34,"completionDate":"2028-01-01"},{"nctId":"NCT05998395","phase":"PHASE1,PHASE2","title":"JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2023-09-28","conditions":["Kohlmeier Degos Disease With Neurologic Involvement","Kohlmeier-Degos Disease"],"enrollment":1,"completionDate":"2025-02-28"},{"nctId":"NCT03865212","phase":"PHASE1","title":"Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2019-06-12","conditions":["Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Choroid Melanoma","Metastatic Melanoma","Metastatic Mucosal Melanoma","Metastatic Uveal Melanoma","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Unresectable Melanoma"],"enrollment":12,"completionDate":"2025-10-12"},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":["Sepsis"],"enrollment":2000,"completionDate":"2031-05-01"},{"nctId":"NCT07244419","phase":"EARLY_PHASE1","title":"Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2026-01-07","conditions":["Hematopoietic Stem Cell Transplantation","Graft Failure"],"enrollment":20,"completionDate":"2029-08"},{"nctId":"NCT06694740","phase":"PHASE2,PHASE3","title":"Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-12","conditions":["Post-aggressive Immunosuppression","Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6","Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C"],"enrollment":170,"completionDate":"2028-04"},{"nctId":"NCT05070247","phase":"PHASE1,PHASE2","title":"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Takeda","startDate":"2022-04-14","conditions":["Pancreatic Cancer","Hepatocellular Cancer","Mesothelioma","Breast Cancer","Gastric Cancer","Esophageal Cancer","Nasopharyngeal Cancer","Kidney Cancer","Squamous Cell Cancer of Head and Neck (SCCHN)","Non-small Cell Lung Cancer (NSCLC), Non-squamous"],"enrollment":61,"completionDate":"2025-01-06"},{"nctId":"NCT04707820","phase":"NA","title":"Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2020-04-16","conditions":["Corona Virus Infection"],"enrollment":51,"completionDate":"2021-04-01"},{"nctId":"NCT07352462","phase":"NA","title":"Volatile Organic Compounds Analysis by GC-MS for Diagnostic of Hospitalised Patients With Respiratory Infections Using Exhaled Breath","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01-01","conditions":["Respiratory Infections","COVID-19","Influenza Virus Infection","Legionella Pneumophila Infections"],"enrollment":777,"completionDate":"2029-02-03"},{"nctId":"NCT07345624","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":["Hepatitis B Virus Infection","Children","Chronic Hepatitis B"],"enrollment":80,"completionDate":"2030-12-31"},{"nctId":"NCT07345611","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":["Hepatitis B Virus Infection","Children","Chronic Hepatitis B"],"enrollment":60,"completionDate":"2030-12-31"},{"nctId":"NCT07349472","phase":"PHASE2","title":"Pentoxifylline in Patients With Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Ihab Elsayed Hassan","startDate":"2026-01-20","conditions":["Inflammatory Bowel Diseases"],"enrollment":60,"completionDate":"2027-02-20"},{"nctId":"NCT07348380","phase":"NA","title":"Volatile Organic Compounds Analysis by PTR-TOF-MS for Screening Respiratory Infections Using Exhaled Breath.","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01-02","conditions":["COVID-19 Infections","Respiratory Infections, Acute"],"enrollment":1665,"completionDate":"2029-06-02"},{"nctId":"NCT07135349","phase":"PHASE2","title":"A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Argo Biopharmaceutical Co., Ltd.","startDate":"2025-09-02","conditions":["Chronic Hepatitis B"],"enrollment":209,"completionDate":"2028-05-08"},{"nctId":"NCT01118130","phase":"","title":"Pharmacogenomics of Drug Safety in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2010-06","conditions":["Multiple Sclerosis"],"enrollment":300,"completionDate":"2025-05"},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":["Hepatitis B","Hepatitis D"],"enrollment":79,"completionDate":"2016-12"},{"nctId":"NCT04379518","phase":"PHASE1,PHASE2","title":"Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2020-11-17","conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Symptomatic COVID-19 Infection Laboratory-Confirmed"],"enrollment":4,"completionDate":"2023-03-15"},{"nctId":"NCT05317000","phase":"PHASE2","title":"5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC","status":"RECRUITING","sponsor":"Barbara Burtness","startDate":"2023-03-23","conditions":["Squamous Cell Carcinoma of Head and Neck"],"enrollment":50,"completionDate":"2028-11-30"},{"nctId":"NCT05162638","phase":"NA","title":"Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pennsylvania","startDate":"2022-04-19","conditions":["Multiple Sclerosis","Healthy"],"enrollment":24,"completionDate":"2027-12"},{"nctId":"NCT03843359","phase":"PHASE1","title":"A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-03-12","conditions":["Neoplasms"],"enrollment":97,"completionDate":"2026-03-31"},{"nctId":"NCT02948426","phase":"PHASE1","title":"Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-02-08","conditions":["Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cancer"],"enrollment":18,"completionDate":"2020-09-29"},{"nctId":"NCT01753570","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-12","conditions":["Chronic Hepatitis C(CHC)"],"enrollment":74,"completionDate":"2015-10"},{"nctId":"NCT00781274","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":["Hepatitis C"],"enrollment":32,"completionDate":"2010-07"},{"nctId":"NCT00780910","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":["Chronic Hepatitis C"],"enrollment":109,"completionDate":"2010-10"},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":["Breast Cancer","Metastatic Breast Cancer","Breast Neoplasm","Breast Cancer Metastatic","End Stage Cancer"],"enrollment":404,"completionDate":"2028-06"},{"nctId":"NCT06999603","phase":"PHASE2","title":"Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection","status":"RECRUITING","sponsor":"Synairgen Research Ltd.","startDate":"2025-09-02","conditions":["Viral Pneumonia"],"enrollment":550,"completionDate":"2027-05"},{"nctId":"NCT07307053","phase":"PHASE1,PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":["Rare Malignant Neoplasm","Advanced Solid Tumors","Metastatic Solid Tumors"],"enrollment":600,"completionDate":"2031-01-31"},{"nctId":"NCT06022029","phase":"PHASE1","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","status":"RECRUITING","sponsor":"OncoNano Medicine, Inc.","startDate":"2023-10-13","conditions":["Triple Negative Breast Cancer","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Lymphoma, Non-Hodgkin","Mantle Cell Lymphoma","Bladder Cancer","Uveal Melanoma, Recurrent","Cervix Cancer","Carcinoma in Situ","Head and Neck Squamous Cell Carcinoma","Skin Cancer","Metastatic Cancer","Tumor, Solid","Tumor Recurrence"],"enrollment":168,"completionDate":"2026-08-29"},{"nctId":"NCT00539591","phase":"PHASE2","title":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-05-09","conditions":["Malignant Melanoma"],"enrollment":29,"completionDate":"2026-05"},{"nctId":"NCT05916274","phase":"NA","title":"Exploration of the Activity of DNA Located Outside of Cellular Nucleus to Amplify Inflammation in Inflammatory Bowel Disease in Children Through Biological Pathway Cyclic GMP-AMP Synthase (cGAS) - Stimulator of Interferon Genes (STING)","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2023-05-31","conditions":["Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis"],"enrollment":40,"completionDate":"2024-02-29"},{"nctId":"NCT06430788","phase":"PHASE2","title":"A Study of Emapalumab for Pediatric Aplastic Anemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-05-21","conditions":["Aplastic Anemia","Cytopenia","Hypocellular Marrow"],"enrollment":35,"completionDate":"2029-05-21"},{"nctId":"NCT04246372","phase":"PHASE2","title":"Tofacitinib for Immune Skin Conditions in Down Syndrome","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-10-21","conditions":["Down Syndrome","Alopecia Areata","Atopic Dermatitis / Eczema","Hidradenitis Suppurativa","Vitiligo","Psoriasis"],"enrollment":47,"completionDate":"2024-10-30"},{"nctId":"NCT06519357","phase":"PHASE2","title":"A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2024-10-28","conditions":["Mild Cognitive Impairment"],"enrollment":23,"completionDate":"2026-03"},{"nctId":"NCT04576156","phase":"PHASE3","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geron Corporation","startDate":"2021-04-12","conditions":["Myelofibrosis"],"enrollment":327,"completionDate":"2028-06-30"},{"nctId":"NCT07249060","phase":"","title":"Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients","status":"RECRUITING","sponsor":"Hospital Universitario Araba","startDate":"2024-01-08","conditions":["Immune-Related Adverse Events","Lupus Erythematosus, Systemic","Sjogren Syndrome","Systemic Sclerosis (SSc)","Inflammatory Myopathies","Solid Tumors"],"enrollment":300,"completionDate":"2026-12"},{"nctId":"NCT07250594","phase":"PHASE2","title":"A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma","status":"NOT_YET_RECRUITING","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2025-12","conditions":["Eosinophilic Asthma"],"enrollment":126,"completionDate":"2026-12"},{"nctId":"NCT01708941","phase":"PHASE2","title":"Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-01-18","conditions":["Recurrent Melanoma","Stage IIIA Cutaneous Melanoma AJCC v7","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7"],"enrollment":88,"completionDate":"2026-03-19"},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":["Multiple Sclerosis"],"enrollment":16,"completionDate":"2025-09-08"},{"nctId":"NCT07069569","phase":"PHASE2","title":"A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-05-30","conditions":["Chronic Hepatitis B"],"enrollment":127,"completionDate":"2027-05-01"},{"nctId":"NCT02743182","phase":"NA","title":"HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients","status":"COMPLETED","sponsor":"José Antonio Carrion","startDate":"2015-01","conditions":["Chronic Hepatitis B (HBeAg-negative)"],"enrollment":119,"completionDate":"2018-11"},{"nctId":"NCT05843786","phase":"PHASE3","title":"Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-06-30","conditions":["Pneumonia, Ventilator-Associated"],"enrollment":132,"completionDate":"2027-07-30"},{"nctId":"NCT01892722","phase":"PHASE3","title":"Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07-26","conditions":["Multiple Sclerosis"],"enrollment":240,"completionDate":"2030-02-18"},{"nctId":"NCT06774235","phase":"PHASE3","title":"Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-07-09","conditions":["Sustained Immunosuppression"],"enrollment":326,"completionDate":"2028-10-09"},{"nctId":"NCT07239830","phase":"NA","title":"Interferon Reference for Older People - REFIPA Study","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-12-01","conditions":["Immunosenescence","Uninfected Older"],"enrollment":62,"completionDate":"2026-12-01"},{"nctId":"NCT06694701","phase":"PHASE2","title":"Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2025-03-22","conditions":["Sepsis"],"enrollment":75,"completionDate":"2026-11"},{"nctId":"NCT04469491","phase":"PHASE2","title":"Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2020-09-20","conditions":["COVID-19","INTERFERON","NEBULIZATION"],"enrollment":74,"completionDate":"2025-12"},{"nctId":"NCT07231276","phase":"PHASE4","title":"Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01-01","conditions":["HBV","Chronic Hepatitis B Virus"],"enrollment":113,"completionDate":"2028-10-01"},{"nctId":"NCT06550141","phase":"PHASE2","title":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2024-09-18","conditions":["Large B-cell Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma","Primary Mediastinal Large B-cell Lymphoma","High-grade B-cell Lymphoma","Follicular Lymphoma"],"enrollment":28,"completionDate":"2027-08-01"},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":["Colorectal Cancer","Hematologic Malignancy","Rectum Cancer","Acute Myeloid Leukemia","Myelodysplastic Syndromes","Acute Lymphoblastic Leukemia","Chronic Myeloid Leukemia","Chronic Lymphocytic Leukemia","Hodgkin Lymphoma","Non Hodgkin Lymphoma","Myeloproliferative Syndrome","Plasma Cell Myeloma","Gastric Cancer","Esophageal Cancer","Esophagus Cancer","Gastric Cancer, Metastatic","Unresectable Esophageal Cancer","Metastatic Esophageal Cancer"],"enrollment":12,"completionDate":"2026-06-01"},{"nctId":"NCT02370329","phase":"PHASE2","title":"P1101 in Treating Patients With Myelofibrosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-08-12","conditions":["Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":11,"completionDate":"2023-11-30"},{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":["Chronic Hepatitis b"],"enrollment":43,"completionDate":"2025-05-21"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Vial","formulations":[{"form":"VIAL","route":"ORAL","productName":""}]},"crossReferences":{"UNII":"M89N0Q7EQR","SPL_ID":"2b563c1a-771f-eb3f-e063-6394a90a618f","chemblId":"CHEMBL2108506"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2015-","companyName":"Bayer Healthcare Pharms","relationship":"Original Developer"}],"publicationCount":189017,"therapeuticAreas":["Immunology"],"applicationNumber":"BLA103471","biosimilarFilings":[],"originalDeveloper":"Bayer Healthcare Pharms","recentPublications":[{"date":"2026 Apr","pmid":"41912985","title":"Associations between sleep disturbance and cerebrospinal fluid Aβ, and shared proteomic signatures in Alzheimer's disease.","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association"},{"date":"2026 Mar 31","pmid":"41912776","title":"Dual function of DOT1L suppresses tumor cell-intrinsic immunogenicity in hepatocellular carcinoma.","journal":"Oncogene"},{"date":"2026 Mar 30","pmid":"41912663","title":"Neuroimmune interferon signals sustain arthritis pain.","journal":"Nature neuroscience"},{"date":"2026 Mar 30","pmid":"41912489","title":"The RASSF1C-HIF-1α axis drives macrophage lipid metabolism to promote pancreatic cancer.","journal":"Cell death & disease"},{"date":"2026 Mar 30","pmid":"41912268","title":"Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.","journal":"Journal for immunotherapy of cancer"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Bayer Healthcare Pharms","companyId":"bayer","modality":"Recombinant protein","firstApprovalDate":"2015","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-02-23T00:00:00.000Z","mah":"BIOGEN","brand_name_local":null,"application_number":"BLA103628"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-07-28T00:00:00.000Z","mah":"BAYER HEALTHCARE PHARMS","brand_name_local":null,"application_number":"BLA103471"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-08-27T00:00:00.000Z","mah":"HORIZON THERAPEUTICS IRELAND DAC","brand_name_local":null,"application_number":"BLA103836"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-05-26T00:00:00.000Z","mah":"SERONO INC","brand_name_local":null,"application_number":"BLA103780"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"BAYER HEALTHCARE PHARMS","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":11,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:40:11.007319+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}